Cloudpharm is a bio-pharmaceutical R&D SME founded in 2016 and established in Greece. We specialize in designing digital platforms with a positive impact on healthcare and the green transiton. We focus on drug discovery, hit-to-lead optimization and drug ecotoxicology testing by integrating AI/ML into computational chemistry know-how: virtual screening, molecular dynamics and QSAR/QSTR pipelines for the identification of safe bioactive compounds. We also develop integrated biomedical platforms for natural product informatics. We provide CRO activities as well as royalties for our developed platforms. We are also continuously looking for opportuities to colaborate with consortia on competitive R&D proposals to advance our technologies to groundbreaking innovations.
The company has participated in 3 successful European-level projects since it was founded in 2016 (FRUITPRINT, ENVIROMED, NEGHTRA) and 3 national-level R&D projects (CLOUDSCREEN, OSTEOME and NEXTGFS), as well as 1 COST Action network, OneHealthDrugs.
Briefly describing our most recent EU/NSRF projects:
ENVIROMED (EU HORIZON) : A just-finished project which built a next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact. FRUITPRINT (MSCA) : An ongoing project concerning the discovery of novel compounds to modify the oxidative stress, cold stress and hypoxia response in post-harvest storage.
ANAPNEO (NSRF): A project, just-approved for funding, focusing on the discovery and development of new pharmaceuticals for idiopathic pulmonary fibrosis, using in silico approaches and preclinical experimentation.
Main topics of potential contribution: in silico mechanistic modelling of molecular or biomarker interactions, computational drug discovery and repurposing, XAI frameworks.
Partner seeks Consortium/Coordinator
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Author
Project Manager / Biomedical Scientist at Cloudpharm P.C
A ligand-protein target based drug repurposing platform aided through ML approaches.
Partner seeks Consortium/Coordinator
Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Author
Project Manager / Biomedical Scientist at Cloudpharm P.C